Brookline Capital Management Upgrades CervoMed (NASDAQ:CRVO) to Strong-Buy

CervoMed (NASDAQ:CRVO) was upgraded by research analysts at Brookline Capital Management from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports. Brookline Capital Management also issued estimates for CervoMed’s Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($1.80) EPS, Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.39) EPS and FY2025 earnings at ($1.71) EPS.

A number of other analysts have also commented on CRVO. Roth Mkm boosted their price target on shares of CervoMed from $7.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday. Canaccord Genuity Group decreased their price target on shares of CervoMed from $65.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. HC Wainwright lowered shares of CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of CervoMed in a research note on Tuesday. Finally, Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.14.

CervoMed Trading Up 161.4 %

NASDAQ:CRVO opened at $6.17 on Tuesday. The company has a fifty day moving average of $2.30 and a 200-day moving average of $8.20. CervoMed has a twelve month low of $1.80 and a twelve month high of $26.38.

Institutional Trading of CervoMed

Several institutional investors have recently made changes to their positions in CRVO. Citizens Financial Group Inc. RI grew its stake in shares of CervoMed by 13.2% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock worth $445,000 after acquiring an additional 3,553 shares in the last quarter. FMR LLC bought a new stake in shares of CervoMed in the 3rd quarter worth $56,000. State Street Corp boosted its holdings in shares of CervoMed by 28.1% in the 3rd quarter. State Street Corp now owns 104,456 shares of the company’s stock worth $1,525,000 after buying an additional 22,903 shares during the last quarter. Barclays PLC boosted its holdings in shares of CervoMed by 323.6% in the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after buying an additional 5,919 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of CervoMed by 13.9% in the 3rd quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock worth $1,678,000 after buying an additional 14,042 shares during the last quarter. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.